Condition: Tuberculosis · Tuberculosis, Pulmonary · Tuberculosis, Lymph Node · Sponsor: Johns Hopkins University
While drug-susceptible tuberculosis (TB) disease in children currently requires four to six months of treatment, most children may be able to be cured with a shorter treatment of more powerful drugs. Shorter treatment may be easier for children to tolerate and finish as well as ease caregiver strain from managing treatment side effects and supporting children over many months. The primary objective of this study is to evaluate if a 2-month regimen (including isoniazid (H), rifapentine (P), pyrazinamide (Z) and moxifloxacin (M)) is as safe and effective as a 4- to 6-month regimen (isoniazid, rifampicin (R), pyrazinamide, ethambutol (E)) in curing drug-susceptible TB disease in children under 10 years old. The study is also evaluating the safety of the HPZM in children with and without HIV.
This description comes directly from the study's public registry record.
Kisten Nolan, MPH, BSN · +14435403993 · knolan2@jh.edu
Always discuss trial participation with your own doctor first.
| Indian Council of Medical Research - National Institute for Research in Tuberculosis | Chennai, India | Recruiting |
| Dr. D.Y. Patil Medical College, Hospital and Research Center | Pune, India | Recruiting |
| Faculty of Medicine, Universitas Padjadjaran | Bandung, Indonesia | Recruiting |
| Instituto Nacional de Saúde (INS) | Maputo, Mozambique | Recruiting |
| Africa Health Research Institute (AHRI) | Durban, South Africa | Recruiting |
| MU-JHU Care Ltd | Kampala, Uganda | Recruiting |
| University of Zambia, School of Medicine | Lusaka, Zambia | Recruiting |
| Arthur Davison Children's Hospital | Ndola, Zambia | Recruiting |
| Harare Health and Research Consortium (HHRC) | Harare, Zimbabwe | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06253715